Drugs for Neglected Diseases initiative-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Drugs for Neglected Diseases initiative-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH142021D
  • |
  • Pages: 25
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Drugs for Neglected Diseases initiative (DNDi) is a research center that discovers and develops new drugs. The center develops therapeutics for the treatment of various diseases. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. DNDi also offers products for treatment of leishmaniasis, sleeping sickness, chagas disease, malaria, paediatric HIV and filarial diseases. The center also offers research programs for various organizations. It collaborates with private biotechnology industries, public institutions, academia and NGOs. The center operates in Switzerland, the US, Kenya, India, Brazil, Malaysia and Japan. DNDi is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 11

Optibrium Enters into Partnership with Imperial College London and DNDi 11

Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 12

Institut Pasteur Korea Enters into Research Agreement with DNDi 13

DNDi Enters into Agreement with Takeda Pharma 14

Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 14

Institut Pasteur Korea and DNDi Enter into Research Agreement 15

Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 16

Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 17

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 18

Sanofi Enters Into Research Collaboration With DNDi 19

Drugs for Neglected Diseases initiative-Key Competitors 20

Key Employees 21

Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Government and Public Interest 24

Jun 16, 2016: Epichem Successful in AusTrade Grant 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25

List of Figures

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Key Facts 1

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Drugs for Neglected Diseases initiative, Deals By Therapy Area, 2011 to YTD 2017 8

Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 11

Optibrium Enters into Partnership with Imperial College London and DNDi 11

Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 12

Institut Pasteur Korea Enters into Research Agreement with DNDi 13

DNDi Enters into Agreement with Takeda Pharma 14

Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 14

Institut Pasteur Korea and DNDi Enter into Research Agreement 15

Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 16

Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 17

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 18

Sanofi Enters Into Research Collaboration With DNDi 19

Drugs for Neglected Diseases initiative, Key Competitors 20

Drugs for Neglected Diseases initiative, Key Employees 21

Drugs for Neglected Diseases initiative, Other Locations 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Drugs for Neglected Diseases initiative, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16140
Site License
USD 500 INR 32280
Corporate User License
USD 750 INR 48420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com